To assess the measurement invariance quality of a short-item employee work assessment questionnaire across key subgroups of pharmaceutical executives. A cross-sectional study with data collected using a nine-item structured questionnaire randomly administered to 406 pharmaceutical executives in Nigeria. Structural equation modelling using Analysis of Moment Structures (AMOS) version 24, and criteria for invariance were absolute change in goodness-of-fit criteria and chi-square test at P < 0.05. Results showed gender [men (n = 293, 72%), women (n = 113, 28%)], [pharmacist (n = 117, 28.8%, non-pharmacist (n = 289, 71.2%)], company type [indigenous (n = 249, 61%), multinational (n = 157, 39%)], and industry experience [low experience; ≤10 years (n = 363, 89%), high experience: ≥10 years (n = 43, 11%)]. Model-fit and construct validity of the instrument were satisfactory. Configural, metric, scalar, and residual invariance of the instrument were confirmed across gender, professional training, and experience levels. Only configural and metric invariance were attained for company type. The developed questionnaire is adequate for assessing pharmacy workforce perception across multiple demographic groups. Invariance testing and reporting are beneficial in social, administrative, and behavioural pharmacy research.
{"title":"Assessment of measurement invariance of psychometric tool for pharmaceutical sales executives: implications for social and behavioural pharmacy research","authors":"T. Oamen, J. Idiake, Oamen Sophia Omorenuwa","doi":"10.1093/jphsr/rmac041","DOIUrl":"https://doi.org/10.1093/jphsr/rmac041","url":null,"abstract":"\u0000 \u0000 \u0000 To assess the measurement invariance quality of a short-item employee work assessment questionnaire across key subgroups of pharmaceutical executives.\u0000 \u0000 \u0000 \u0000 A cross-sectional study with data collected using a nine-item structured questionnaire randomly administered to 406 pharmaceutical executives in Nigeria. Structural equation modelling using Analysis of Moment Structures (AMOS) version 24, and criteria for invariance were absolute change in goodness-of-fit criteria and chi-square test at P < 0.05.\u0000 \u0000 \u0000 \u0000 Results showed gender [men (n = 293, 72%), women (n = 113, 28%)], [pharmacist (n = 117, 28.8%, non-pharmacist (n = 289, 71.2%)], company type [indigenous (n = 249, 61%), multinational (n = 157, 39%)], and industry experience [low experience; ≤10 years (n = 363, 89%), high experience: ≥10 years (n = 43, 11%)]. Model-fit and construct validity of the instrument were satisfactory. Configural, metric, scalar, and residual invariance of the instrument were confirmed across gender, professional training, and experience levels. Only configural and metric invariance were attained for company type.\u0000 \u0000 \u0000 \u0000 The developed questionnaire is adequate for assessing pharmacy workforce perception across multiple demographic groups. Invariance testing and reporting are beneficial in social, administrative, and behavioural pharmacy research.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47085620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rana Al-Nimri, A. Akour, V. Kasabri, A. Al-Samydai
The aim of the study is to assess the extent of CAM use, with emphasis on herbs, in treating gynecological disorders, and their perceived efficacy and safety. This was a mixed-method study of two parts (cross-sectional quantitative and qualitative study) of 338 women suffering from gynecological disorders during the last 3 months. Data were collected using a self-administered questionnaire of three parts: demographics, medical history and the CAM use patterns. Qualitative part was conducted by a 20-min verbal face-to-face interview. During the last 3 months, 232 (68.64%) of participants had used CAM for various gynaecological conditions, of which, 135 (58.19%) used herbal remedies. Almost half of participants have a good awareness about CAM definition, and they mainly used CAM before or concurrently with traditional medicines. This study provides an overview of various CAM remedies used to treat gynaecological disorders in the Jordanian society, which would draw attention to the necessity of conducting interventional studies to evaluate the efficacy and safety of CAM in treating gynaecological disorders, either as stand-alone or adjuvant treatment.
{"title":"The use of complementary and alternative medicine in fertility and gynaecological disorders in Jordan: a mixed-method descriptive study","authors":"Rana Al-Nimri, A. Akour, V. Kasabri, A. Al-Samydai","doi":"10.1093/jphsr/rmac039","DOIUrl":"https://doi.org/10.1093/jphsr/rmac039","url":null,"abstract":"\u0000 \u0000 \u0000 The aim of the study is to assess the extent of CAM use, with emphasis on herbs, in treating gynecological disorders, and their perceived efficacy and safety.\u0000 \u0000 \u0000 \u0000 This was a mixed-method study of two parts (cross-sectional quantitative and qualitative study) of 338 women suffering from gynecological disorders during the last 3 months. Data were collected using a self-administered questionnaire of three parts: demographics, medical history and the CAM use patterns. Qualitative part was conducted by a 20-min verbal face-to-face interview.\u0000 \u0000 \u0000 \u0000 During the last 3 months, 232 (68.64%) of participants had used CAM for various gynaecological conditions, of which, 135 (58.19%) used herbal remedies. Almost half of participants have a good awareness about CAM definition, and they mainly used CAM before or concurrently with traditional medicines.\u0000 \u0000 \u0000 \u0000 This study provides an overview of various CAM remedies used to treat gynaecological disorders in the Jordanian society, which would draw attention to the necessity of conducting interventional studies to evaluate the efficacy and safety of CAM in treating gynaecological disorders, either as stand-alone or adjuvant treatment.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43683335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Takaki, Erina Kaneko, Masanobu Sonoda, Toru Yamano, I. Ieiri
This study aimed to identify drug-related problems (DRPs) using data regarding the communication of pharmacists with prescribers over the phone at a community pharmacy. Furthermore, we elucidated the frequency of the sources of information for detecting each DRP and evaluated the decisions made by the prescribers for each DRP. This cross-sectional study was conducted at a community pharmacy in Fukuoka Prefecture, Japan. We anonymously collected data obtained by pharmacists through contacting prescribers over the phone relating to any problems or doubts found in prescriptions between April 2016 and March 2019. We classified the data and identified DRPs. We elucidated the frequency of sources of information for detecting each DRP using descriptive analyses and evaluated prescribers’ decisions regarding each DRP via multivariate Poisson regression analyses. Of the 95 023 prescriptions, 5073 DRPs were identified (5073/95 023 = 5.34%). The most frequent DRP was inappropriate dosage and administration (1349/5073 = 26.59%), followed by non-adherence (1272/5073 = 25.07%) and incorrect prescription periods (889/5073 = 17.52%). Patient interviews were the most frequent sources of information for detecting following DRPs: non-adherence (1057/1272 = 83.10%), untreated indication (590/631 = 93.50%) and adverse drug reactions (80/107 = 74.77%). Most of the DRPs were resolved by making changes to the prescriptions (4571/5073 = 90.10%). Inappropriate dosage and administration and non-adherence issues were the most frequent DRPs in a Japanese community pharmacy. Patient interviews were an important source of information for detecting DRPs. Further research is warranted to address the impact of DRPs on patient safety.
{"title":"Drug-related problems identified at a Japanese community pharmacy: a cross-sectional study","authors":"H. Takaki, Erina Kaneko, Masanobu Sonoda, Toru Yamano, I. Ieiri","doi":"10.1093/jphsr/rmac035","DOIUrl":"https://doi.org/10.1093/jphsr/rmac035","url":null,"abstract":"\u0000 \u0000 \u0000 This study aimed to identify drug-related problems (DRPs) using data regarding the communication of pharmacists with prescribers over the phone at a community pharmacy. Furthermore, we elucidated the frequency of the sources of information for detecting each DRP and evaluated the decisions made by the prescribers for each DRP.\u0000 \u0000 \u0000 \u0000 This cross-sectional study was conducted at a community pharmacy in Fukuoka Prefecture, Japan. We anonymously collected data obtained by pharmacists through contacting prescribers over the phone relating to any problems or doubts found in prescriptions between April 2016 and March 2019. We classified the data and identified DRPs. We elucidated the frequency of sources of information for detecting each DRP using descriptive analyses and evaluated prescribers’ decisions regarding each DRP via multivariate Poisson regression analyses.\u0000 \u0000 \u0000 \u0000 Of the 95 023 prescriptions, 5073 DRPs were identified (5073/95 023 = 5.34%). The most frequent DRP was inappropriate dosage and administration (1349/5073 = 26.59%), followed by non-adherence (1272/5073 = 25.07%) and incorrect prescription periods (889/5073 = 17.52%). Patient interviews were the most frequent sources of information for detecting following DRPs: non-adherence (1057/1272 = 83.10%), untreated indication (590/631 = 93.50%) and adverse drug reactions (80/107 = 74.77%). Most of the DRPs were resolved by making changes to the prescriptions (4571/5073 = 90.10%).\u0000 \u0000 \u0000 \u0000 Inappropriate dosage and administration and non-adherence issues were the most frequent DRPs in a Japanese community pharmacy. Patient interviews were an important source of information for detecting DRPs. Further research is warranted to address the impact of DRPs on patient safety.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41375767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There is a widely held but previously unsubstantiated belief that prescribers tend to consider and use a limited set of medications when making prescribing decisions. This study aimed to enhance understanding of the process of prescribing decision making in a real-world context. Using constructivist grounded theory methodology, we conducted semi-structured interviews with 11 healthcare providers in Georgia state. The providers, most of whom are physicians of different specialties, shared their perspectives about prescribing decision making and their perceptions about using a limited set of medications in daily practice. Three themes emerged from the qualitative analysis: (1) prescribers recognized the existence of ‘small individual formularies’ and considered it helpful in simplifying prescribing decision making; (2) healthcare providers employed an algorithm to initiate and step up drug therapy for patients; (3) formulary and patient affordability played a vital role in prescribing. Physicians and other prescribers consider and use a limited set of prescription drugs based on their internal prescribing behaviour algorithm. Strategies could be developed to help stakeholders use this information to improve medication use.
{"title":"The potential existence of ‘Small Individual Formulary’ in prescribing behaviour: a qualitative semi-structured interview study","authors":"Yu Wang, M. Perri","doi":"10.1093/jphsr/rmac031","DOIUrl":"https://doi.org/10.1093/jphsr/rmac031","url":null,"abstract":"\u0000 \u0000 \u0000 There is a widely held but previously unsubstantiated belief that prescribers tend to consider and use a limited set of medications when making prescribing decisions. This study aimed to enhance understanding of the process of prescribing decision making in a real-world context.\u0000 \u0000 \u0000 \u0000 Using constructivist grounded theory methodology, we conducted semi-structured interviews with 11 healthcare providers in Georgia state. The providers, most of whom are physicians of different specialties, shared their perspectives about prescribing decision making and their perceptions about using a limited set of medications in daily practice.\u0000 \u0000 \u0000 \u0000 Three themes emerged from the qualitative analysis: (1) prescribers recognized the existence of ‘small individual formularies’ and considered it helpful in simplifying prescribing decision making; (2) healthcare providers employed an algorithm to initiate and step up drug therapy for patients; (3) formulary and patient affordability played a vital role in prescribing.\u0000 \u0000 \u0000 \u0000 Physicians and other prescribers consider and use a limited set of prescription drugs based on their internal prescribing behaviour algorithm. Strategies could be developed to help stakeholders use this information to improve medication use.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43451533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Objectives Pharmacy practice journals are considered the main player in promoting pharmacy practice research and the pharmacy profession globally. The current study aimed to explore and analyze literature on the COVID-19 pandemic published in pharmacy practice journals. Methods COVID-19 research articles were extracted from 32 pharmacy practice journals indexed in Scopus for the study period from 01 January 2020, up until 31 December 2021 Key findings A total of 581 documents were found with an average of 4.5 authors per article and 4.8 citations per document. The retrieved documents were published in 28 pharmacy practice-related journals with the Research in Social and Administrative Pharmacy and the American Journal of Health System Pharmacy journals being the leaders in this field. The major findings of the analysis indicated (1) a limited number of contributing countries with limited author-author interactions and cross country collaboration; (2) specific topics were encountered, mainly hospital pharmacy services, survey studies on knowledge, and pharmacy education; (3) several contributing countries in the Middle East, mainly Saudi Arabia; Egypt, and Jordan contributed to the retrieved documents, and (4) the highly-cited documents discussed issues related to pharmacy services and role of the community pharmacists during the pandemic. Conclusion Research activity on COVID-19 in pharmacy practice journals represents the commitment of researchers and professionals to transform and promote the profession of pharmacy. Research on pharmacy practice and pharmacists in low- and middle-income countries during pandemics needs to be prioritized by scholars and journal editors.
{"title":"Bibliometric analysis of COVID-19 research publications in pharmacy practice journals","authors":"W. Sweileh","doi":"10.1093/jphsr/rmac026","DOIUrl":"https://doi.org/10.1093/jphsr/rmac026","url":null,"abstract":"Abstract Objectives Pharmacy practice journals are considered the main player in promoting pharmacy practice research and the pharmacy profession globally. The current study aimed to explore and analyze literature on the COVID-19 pandemic published in pharmacy practice journals. Methods COVID-19 research articles were extracted from 32 pharmacy practice journals indexed in Scopus for the study period from 01 January 2020, up until 31 December 2021 Key findings A total of 581 documents were found with an average of 4.5 authors per article and 4.8 citations per document. The retrieved documents were published in 28 pharmacy practice-related journals with the Research in Social and Administrative Pharmacy and the American Journal of Health System Pharmacy journals being the leaders in this field. The major findings of the analysis indicated (1) a limited number of contributing countries with limited author-author interactions and cross country collaboration; (2) specific topics were encountered, mainly hospital pharmacy services, survey studies on knowledge, and pharmacy education; (3) several contributing countries in the Middle East, mainly Saudi Arabia; Egypt, and Jordan contributed to the retrieved documents, and (4) the highly-cited documents discussed issues related to pharmacy services and role of the community pharmacists during the pandemic. Conclusion Research activity on COVID-19 in pharmacy practice journals represents the commitment of researchers and professionals to transform and promote the profession of pharmacy. Research on pharmacy practice and pharmacists in low- and middle-income countries during pandemics needs to be prioritized by scholars and journal editors.","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44480262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dion C Allen, Silvia E Rabionet, Ioana Popovici, Carmen D Zorrilla
Objective: One in four persons living with HIV in the USA is a woman. While the annual HIV diagnoses for 2019 decreased by approximately 9% when compared with 2015, this decrease was seen in men, while the rates remained stable for women. Pre-exposure prophylaxis (PrEP) is one major biomedical tool that could benefit women at risk of HIV. However, women only account for approximately 5% of PrEP users annually. The objective of this study is to identify and address the gender disparity in PrEP use.
Methods: This study used epidemiological data from the AIDSVu database to confirm the presence of a gender disparity in PrEP use across the USA. Cross-sectional data from 2019 showed that PrEP use was significantly higher in men, which suggested the existence of a disparity. The PrEP-to-Need ratio was then used to examine the trends in PrEP use relative to the rate of HIV infections, from 2012 to 2019, and to confirm the existence of the gender disparity in PrEP use.
Key findings: There is a marked gender disparity in PrEP use. This disparity is widening and therefore demands more attention to women at risk of HIV. Some recommendations for addressing the disparity include the following: raising awareness, capacity building for providers, scaling up efforts to better reach women at risk of HIV and additional research to understand the drivers of the disparity.
Conclusions: Policy makers could therefore prioritize the health outcomes of women by promoting research and education aimed at extending PrEP offerings to effectively reach women.
{"title":"Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention.","authors":"Dion C Allen, Silvia E Rabionet, Ioana Popovici, Carmen D Zorrilla","doi":"10.1093/jphsr/rmac025","DOIUrl":"https://doi.org/10.1093/jphsr/rmac025","url":null,"abstract":"<p><strong>Objective: </strong>One in four persons living with HIV in the USA is a woman. While the annual HIV diagnoses for 2019 decreased by approximately 9% when compared with 2015, this decrease was seen in men, while the rates remained stable for women. Pre-exposure prophylaxis (PrEP) is one major biomedical tool that could benefit women at risk of HIV. However, women only account for approximately 5% of PrEP users annually. The objective of this study is to identify and address the gender disparity in PrEP use.</p><p><strong>Methods: </strong>This study used epidemiological data from the AIDSVu database to confirm the presence of a gender disparity in PrEP use across the USA. Cross-sectional data from 2019 showed that PrEP use was significantly higher in men, which suggested the existence of a disparity. The PrEP-to-Need ratio was then used to examine the trends in PrEP use relative to the rate of HIV infections, from 2012 to 2019, and to confirm the existence of the gender disparity in PrEP use.</p><p><strong>Key findings: </strong>There is a marked gender disparity in PrEP use. This disparity is widening and therefore demands more attention to women at risk of HIV. Some recommendations for addressing the disparity include the following: raising awareness, capacity building for providers, scaling up efforts to better reach women at risk of HIV and additional research to understand the drivers of the disparity.</p><p><strong>Conclusions: </strong>Policy makers could therefore prioritize the health outcomes of women by promoting research and education aimed at extending PrEP offerings to effectively reach women.</p>","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547494/pdf/rmac025.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10205677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammed Shazad, F. El‑Dahiyat, F. Javid, Neda Zare, Besime Ozbek, J. Stephenson, Z. Babar
The objective of the literature review is to collect data on how cancer medication pricing affects affordability and availability around the world. A literature search was carried out between 12 October 2020 and 2 December 2020, articles were selected based on them being available as full texts online and written in English. The keywords used were: ‘cancer’, ‘medicines’, ‘drug’, ‘drugs’, ‘pharmaceuticals’, ‘price’, ‘prices’, ‘pricing’. The collective search produced a total of 10 725 articles. After a refining process, any articles considered unnecessary and potential duplications were eliminated, and 16 research articles were included in the final analysis. The results were included in the following categories: (a) high-income countries, (b) low- and middle-income countries (LMICs), (c) originator cancer drug prices, (d) generic drug prices, (e) breast and colorectal cancer drug pricing. The expensive pricing of oncology medications is typically expected to be an obstacle for developing nations; however, the soaring prices have been found increasingly challenging for high-income countries. Within Europe, variations exist between countries in government expenditure and cancer drug prices. Originator cancer drug prices tend to be most expensive in Sweden, Denmark, Switzerland and Germany whereas Greece, Spain, Portugal and the UK had among the lowest recorded prices. The high cost of cancer drugs coupled with low availability rates have resulted in restricted access for many LMICs as monthly medicinal costs are often greater than yearly incomes. The literature has shown the increasing trend of cancer drug pricing. The synthesis has also shown that cancer treatments are unaffordable in many developing countries resulting in most cancer deaths occurring in LMICs. Furthermore, governments cannot effectively challenge patented drug prices until the expiry of the patent.
{"title":"Analysis of cancer drug prices: a narrative review of literature","authors":"Mohammed Shazad, F. El‑Dahiyat, F. Javid, Neda Zare, Besime Ozbek, J. Stephenson, Z. Babar","doi":"10.1093/jphsr/rmac027","DOIUrl":"https://doi.org/10.1093/jphsr/rmac027","url":null,"abstract":"\u0000 \u0000 \u0000 The objective of the literature review is to collect data on how cancer medication pricing affects affordability and availability around the world.\u0000 \u0000 \u0000 \u0000 A literature search was carried out between 12 October 2020 and 2 December 2020, articles were selected based on them being available as full texts online and written in English. The keywords used were: ‘cancer’, ‘medicines’, ‘drug’, ‘drugs’, ‘pharmaceuticals’, ‘price’, ‘prices’, ‘pricing’. The collective search produced a total of 10 725 articles. After a refining process, any articles considered unnecessary and potential duplications were eliminated, and 16 research articles were included in the final analysis. The results were included in the following categories: (a) high-income countries, (b) low- and middle-income countries (LMICs), (c) originator cancer drug prices, (d) generic drug prices, (e) breast and colorectal cancer drug pricing. The expensive pricing of oncology medications is typically expected to be an obstacle for developing nations; however, the soaring prices have been found increasingly challenging for high-income countries. Within Europe, variations exist between countries in government expenditure and cancer drug prices. Originator cancer drug prices tend to be most expensive in Sweden, Denmark, Switzerland and Germany whereas Greece, Spain, Portugal and the UK had among the lowest recorded prices. The high cost of cancer drugs coupled with low availability rates have resulted in restricted access for many LMICs as monthly medicinal costs are often greater than yearly incomes.\u0000 \u0000 \u0000 \u0000 The literature has shown the increasing trend of cancer drug pricing. The synthesis has also shown that cancer treatments are unaffordable in many developing countries resulting in most cancer deaths occurring in LMICs. Furthermore, governments cannot effectively challenge patented drug prices until the expiry of the patent.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46785722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Predatory journals and conferences","authors":"A. Wertheimer","doi":"10.1093/jphsr/rmac018","DOIUrl":"https://doi.org/10.1093/jphsr/rmac018","url":null,"abstract":"","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46881688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Mohamed Dharvees, D. Sandy Crasta, Steby Mol Stephen, Anmaria Thomas, P. Pereira, M. Ramesh, C. Sri Harsha, Jehath Syed
To assess the rate of medication adherence, facilitators and barriers to medication adherence among elderly. A cross-sectional study was conducted to assess the medication adherence level and the patient reported facilitators and barriers using medication adherence rating scale and a prevalidated questionnaire, respectively amongst the geriatric patients who were hospitalised in a south India tertiary care hospital. Data thus collected were categorically analysed. Predictors were assessed using odds ratio at 95% confidence interval. A total of 401 patients were enrolled, majority [220 (54.86%)] were adherent to the medications. The barriers identified included forgetfulness, carelessness, lack of awareness about the disease and medication, illiteracy, lack of regular follow up and visit, social stigma on disease, polypharmacy and adverse effects. The facilitators included good access to the health care system, patient counselling, regular follow-up, and refill. The age group of 71–80 years [OR 2.02 (95% CI, 1.31–3.13)], illiteracy [OR 2.34 (95% CI 1.38–3.98)], single as marital status [OR 3.64 (95% CI, 1.13–11.67)], comorbidities (≥5) [OR 3.91 (95% CI, 1.78–8.60)], discharge medications (>11) [OR 3.11 (95% CI, 1.55–6.26)], lack of awareness about the disease [OR 1.99 (95% CI, 1.30–3.032)] were found to be significant predisposing factors. This study reveals as several predictive factors were identified for medication nonadherence which can aid in developing strategies to improve medication adherence.
{"title":"Facilitators and barriers of medication adherence amongst the geriatrics: a cross-sectional study","authors":"T. Mohamed Dharvees, D. Sandy Crasta, Steby Mol Stephen, Anmaria Thomas, P. Pereira, M. Ramesh, C. Sri Harsha, Jehath Syed","doi":"10.1093/jphsr/rmac023","DOIUrl":"https://doi.org/10.1093/jphsr/rmac023","url":null,"abstract":"\u0000 \u0000 \u0000 To assess the rate of medication adherence, facilitators and barriers to medication adherence among elderly.\u0000 \u0000 \u0000 \u0000 A cross-sectional study was conducted to assess the medication adherence level and the patient reported facilitators and barriers using medication adherence rating scale and a prevalidated questionnaire, respectively amongst the geriatric patients who were hospitalised in a south India tertiary care hospital. Data thus collected were categorically analysed. Predictors were assessed using odds ratio at 95% confidence interval.\u0000 \u0000 \u0000 \u0000 A total of 401 patients were enrolled, majority [220 (54.86%)] were adherent to the medications. The barriers identified included forgetfulness, carelessness, lack of awareness about the disease and medication, illiteracy, lack of regular follow up and visit, social stigma on disease, polypharmacy and adverse effects. The facilitators included good access to the health care system, patient counselling, regular follow-up, and refill. The age group of 71–80 years [OR 2.02 (95% CI, 1.31–3.13)], illiteracy [OR 2.34 (95% CI 1.38–3.98)], single as marital status [OR 3.64 (95% CI, 1.13–11.67)], comorbidities (≥5) [OR 3.91 (95% CI, 1.78–8.60)], discharge medications (>11) [OR 3.11 (95% CI, 1.55–6.26)], lack of awareness about the disease [OR 1.99 (95% CI, 1.30–3.032)] were found to be significant predisposing factors.\u0000 \u0000 \u0000 \u0000 This study reveals as several predictive factors were identified for medication nonadherence which can aid in developing strategies to improve medication adherence.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49611933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anam Azhar, Syed Wasif Gillani, Nada Jiaan, V. Menon, Semira Abdi, H. A. Rathore
This study aimed to determine patient satisfaction with the following pharmacist-led services for inpatients in tertiary care hospitals. Studies were identified from different databases from 2012 to 2020. A total of 1910 articles were identified using the search strategies out of which 1153 were rejected based on the review of titles and abstracts. The search criteria were the roles of inpatient pharmacists and patient satisfaction with inpatient pharmacy services. Multiple keywords were used such as ‘patient satisfaction’/‘inpatient pharmacist’/‘pharmacist hospital services’/‘clinical pharmacist roles’. The quality of each study was measured using the mixed methods appraisal tool, and the same was used to evaluate the risk of bias as well. A total of 11 cross-sectional studies were included in the evidence synthesis of this meta-analysis. Three studies tested the satisfaction of patients with inpatient counselling with a sample size of n = 742. The odd ratio (OR) was 215.33 (141.77 to 327.05) [95% confidence interval (CI)] showed a significant patient satisfaction (P = 0.00001) with the pharmacist’s inpatient counselling (I2 = 0%). Studies showed a statistically significant satisfaction of patients with discharge counselling P < 0.00001 and OR 55.74 (35.93 to 86.49) and heterogeneity I2 = 0%. In a total of five studies, the healthcare professional (HCP) satisfaction with pharmacist services was reported, and satisfied and unsatisfied HCPs were n = 801 and n = 362, respectively. Results showed high satisfaction (P < 0.00001) and OR 4.62 (95% CI, 3.89 to 5.48). This meta-analysis concluded that clinical pharmacist services in an inpatient setting have a significant impact on increasing patient satisfaction with their treatment. The clinical pharmacist services are not very well implemented and are limited in some hospitals, but patients who have received these services were highly satisfied and expected to receive them more often.
{"title":"Patient satisfaction with inpatient pharmacy services at tertiary care setting—a meta-analysis of recent literature","authors":"Anam Azhar, Syed Wasif Gillani, Nada Jiaan, V. Menon, Semira Abdi, H. A. Rathore","doi":"10.1093/jphsr/rmac022","DOIUrl":"https://doi.org/10.1093/jphsr/rmac022","url":null,"abstract":"\u0000 \u0000 \u0000 This study aimed to determine patient satisfaction with the following pharmacist-led services for inpatients in tertiary care hospitals.\u0000 \u0000 \u0000 \u0000 Studies were identified from different databases from 2012 to 2020. A total of 1910 articles were identified using the search strategies out of which 1153 were rejected based on the review of titles and abstracts. The search criteria were the roles of inpatient pharmacists and patient satisfaction with inpatient pharmacy services. Multiple keywords were used such as ‘patient satisfaction’/‘inpatient pharmacist’/‘pharmacist hospital services’/‘clinical pharmacist roles’. The quality of each study was measured using the mixed methods appraisal tool, and the same was used to evaluate the risk of bias as well.\u0000 \u0000 \u0000 \u0000 A total of 11 cross-sectional studies were included in the evidence synthesis of this meta-analysis. Three studies tested the satisfaction of patients with inpatient counselling with a sample size of n = 742. The odd ratio (OR) was 215.33 (141.77 to 327.05) [95% confidence interval (CI)] showed a significant patient satisfaction (P = 0.00001) with the pharmacist’s inpatient counselling (I2 = 0%). Studies showed a statistically significant satisfaction of patients with discharge counselling P < 0.00001 and OR 55.74 (35.93 to 86.49) and heterogeneity I2 = 0%. In a total of five studies, the healthcare professional (HCP) satisfaction with pharmacist services was reported, and satisfied and unsatisfied HCPs were n = 801 and n = 362, respectively. Results showed high satisfaction (P < 0.00001) and OR 4.62 (95% CI, 3.89 to 5.48).\u0000 \u0000 \u0000 \u0000 This meta-analysis concluded that clinical pharmacist services in an inpatient setting have a significant impact on increasing patient satisfaction with their treatment. The clinical pharmacist services are not very well implemented and are limited in some hospitals, but patients who have received these services were highly satisfied and expected to receive them more often.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45501773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：